


Product Data Sheet

Cas No.:	866323-14-0	Cat. No:	PL01351
Product Name:	Belinostat		
Product synonym:	贝利司他;(E)-N-羟基-3-[3-(N-苯基氨磺酰基)苯基]丙烯酰胺;(E)-N-羟基-3-(3-(N-苯基磺胺基)苯基)丙烯酰胺		
Chemical name:	Belinostat		
MF:	C15H14N2O4S	FW:	318.3477
Purity:	≥99%	Batch No.:	-
Storage:			
Structural formula:			
λmax:	-	Formulation:	-
Solubility :			
SMILES :	S(C1=C([H])C([H])=C([H])C(/C/[H])=C([H])/C(N([H])O[H])=O)=C1[H])(N([H])C1C([H])=C([H])C([H])=C([H])C=1[H])(=O)=O		
InChI Code:	-		
InChI Key:			
WARNING This product is not for human or veterinary use.			

Product Description

Belinostat (PXD101; PX105684) 是一种有效的 HDAC 抑制剂，在 HeLa 细胞提取物中的 IC₅₀ 为 27 nM。

生物活性	Belinostat (PXD101; PX105684) is a potent HDAC inhibitor with an IC ₅₀ of 27 nM in HeLa cell extracts.
IC ₅₀ & Target[1][2]	HDAC6 82 nM (IC ₅₀) HDAC 27 nM (IC ₅₀)
体外研究(In Vitro)	Belinostat (PXD101) induces a concentration-dependent (0.2-5 μM) increase in acetylation of histone H4 in tumor cell lines. Belinostat is cytotoxic in vitro in a number of tumor cell lines with IC ₅₀ s in the range 0.2-3.4 μM as determined by a clonogenic assay and induces apoptosis. Belinostat inhibits the growth of a number of human tumor cell lines in vitro with IC ₅₀ s determined by a clonogenic assay in the range 0.2-3.4 μM. Belinostat (PXD101) is a potent histone deacetylase (HDAC) inhibitor, potently inhibits the enzymatic activity of purified recombinant HDAC6 (IC ₅₀ of 82 nM). has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)	Treatment of nude mice bearing human ovarian and colon tumor xenografts with Belinostat (10-40 mg/kg/day i.p.) daily for 7 days causes a significant dose-dependent growth delay with no obvious signs of toxicity to the mice. Growth delay is also observed for xenografts of cisplatin-resistant ovarian tumor cells. A marked increase in acetylation of H4 is detected in blood and tumor of mice 3 h after treatment with Belinostat (PXD101). The inhibition of growth of human tumor xenografts in mice, with no apparent toxicity. Belinostat (PXD101) displays single-agent antitumor activity on human A2780 ovarian cancer s.c. xenografts which is enhanced via combination therapy with Carboplatin. has not independently confirmed the accuracy of these methods. They are for reference only.
包装储存	Powder -20°C 3 years; 4°C 2 years
溶解度数据	In Vitro: DMSO : 100 mg/mL (314.12 mM; Need ultrasonic)配制储备液